US3682953A - Substituted 5-nitrofuryl-pyrazoles - Google Patents

Substituted 5-nitrofuryl-pyrazoles Download PDF

Info

Publication number
US3682953A
US3682953A US15209A US3682953DA US3682953A US 3682953 A US3682953 A US 3682953A US 15209 A US15209 A US 15209A US 3682953D A US3682953D A US 3682953DA US 3682953 A US3682953 A US 3682953A
Authority
US
United States
Prior art keywords
nitro
pyrazole
furyl
formula
furaldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US15209A
Other languages
English (en)
Inventor
Graham Arton Howarth
William Hoyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3682953A publication Critical patent/US3682953A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the alkyl moiety constituting or forming part of the group R contains from one to five carbon atoms, but is preferably a straightor branched-chain radical containing from one to three carbon atoms.
  • alkyl moieties include the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertiary butyl and n-pentyl groups. If R represents a carbalkoxy group, then it is preferred that it should be an ethoxy-carbonyl group.
  • the present invention also provides salts of nitrofuryl-pyrazoles of formula I with organic and inorganic acids.
  • organic and inorganic acids examples include hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulphonic, ethandisulphonic, acetic, trichloroacetic, oxalic, succinic, maleic, fumaric, malic, tartaric, citric and mandelic acids.
  • the compounds of the present invention are prepared by reacting the corresponding nitrofurylnitrilimine, which in one of its canonical forms may be represented by the formula II,
  • X represents a halogen atom, with a base.
  • the process may, if desired, be effected in the presence of a further conventional hydrogen halide acceptor.
  • the halogen present in the halohydrazone of formula III is preferably chlorine or bromine.
  • the nitrofuryl-a-halo-hydrazones of formula III are new compounds. They are produced, for example, by reacting the corresponding nitrofuryl-hydrazones having the formula IV,
  • the present invention also provides a modification of the process for producing a nitrofuryl-pyrazole of formula I, which comprises reacting the corresponding nitrofuryl-hydrazone of formula IV with an N-halo compound and treating the reaction mixture thus ob tained with malononitrile in the presence of a base.
  • the intermediate product from the reaction of the nitrofuryl-hydrazone of formula IV with the N-halo compound is not isolated before contacting with the malononitrile.
  • the alkyl-substituted hydrazones of formula IV are prepared by reacting 5-nitro-2-furylaldehyde with an alkylor carbalkoxyhydrazine in an anhydrous solvent, e.g. anhydrous ethanol, according to methods described by Howarth et al, J. Org. Chem, 28, 864(1963), Sasaki, Pharm. P. Bull. (Japan), 2, 123(1954) and British Pat. No. 905,459. Hydroxyalkylhydrazones, although new, can also be prepared in a similar manner described in the above-cited references.
  • anhydrous solvent e.g. anhydrous ethanol
  • N-halo compounds which may be used in both these processes are N-halo benzotriazoles and N-halo succinimides.
  • N-halo succinimides the N-chloro compound may be used, but the N-bromo derivative is preferred.
  • the compounds of the invention having formula I have valuable antimicrobial properties, and in particular having antibacterial, anthelminthic, antiprotozoal, coccidiostatic, trypanocidal and antimalarial activity of value in human or veterinary medicine.
  • the compounds are particularly valuable in the treatment of infections of the intestinal and urinary tracts.
  • the compounds may also be used to protect a high molecular weight hydrophobic or other organic material susceptible to bacterial or other microbial deterioration by contacting, impregnating or otherwise treating the organic material with the compounds in amounts up to about 5 percent by weight.
  • the compounds also find application as growth-promoting additives to animal feedstuffs, to which they may be added in proportions of from 5 to 500 parts per million.
  • the antimicrobial activity of the compounds of formula I can be demonstrated in a variety of in vitro and in vivo tests.
  • standard in vitro tests for example 5- amino-4-cyanol -methyl-3-( 5-nitro-2-furyl )-pyrazole and 5-amino-4-cyano-l -(2-hydroxyethyl)-3-(5-nitro- 2-furyl)-pyrazole, have an excellent inhibiting activity on the growth of Staphylococcus, Escherichia coli, Klebsiella, Salmonella, Candida alb. and other bacteria.
  • mice are infected by intraperitoneal injection of 0.2 ml of a suspension of pathogenic germs which causes a mortality rate of 100 percent in a group of untreated control mice.
  • the test compound is ad-v ministered per os by means of a stomach tube, twice on the day of infection.
  • the duration of the therapy is adapted to the virulence of the pathogenic germ.
  • the mice are now observed and the surviving mice are counted on the fourth day. For each dose of the test compound, the cumulative mortality is then calculated according to the method of L]. Reed and M. Muench, Am.J.I-lyg. 27, 493 (1938).
  • the curative dosage necessary for the survival of 50 percent of the test animals is calculated by the same method of Reed and Muench.
  • the CD thus determined is found to be far below the toxic dose, and indicates that 5-amino-4-cyano-l-( 2-hydroxyethyl)-3-(5-nitro-2-furyl)-pyrazole has an excellent activity against Staphylococcus aureus.
  • the compounds of formula I are administered orally in daily dosages of from about lto about 50 mg/kg, although the exact dosage has to be adjusted to the type of infection, the age, weight and the particular condition of the host being treated.
  • the compounds of formula I are administered advantageously in form of pharmaceutical compositions comprising an antimicrobially effective amount of a compound of formula I or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.
  • the type of carrier actually used depends to a great extent on the intended application; for external use, for example in disinfecting healthy skin, disinfecting wounds and in treating dermatoses and infections of the mocus membranes caused by bacteria, ointments, powders and tinctures are used in particular.
  • the ointment bases may be anhydrous, for instance they can consist of mixtures of wool fat and soft parafi'm, or they can consist of aqueous emulsions in which the active substance is suspended.
  • Suitable carriers for powders are, for instance, rice starch and other starches; the bulk weight of the carriers may be lighter, if desired, for example by adding highly dispersed silicic acid, or may be made heavier by adding talcum.
  • the tinctures may contain at least one active ingredient of the formula I in aqueous ethanol, in particular 45 to 75 percent ethanol, to which 10 percent to 20 percent of glycerol may be added, if desired.
  • Solutions prepared from polyethylene glycol and other conventional solubility promoters, and also, optionally, from emulsifying agents, may be used with particular advantage in disinfecting healthy skin.
  • the content of active ingredient in pharmaceutical compositions for external application is preferable in the range of from 0.1 percent to 5 percent.
  • Gargles or concentrates for their preparation, and tablets for slow dissolution in the mouth are suitable for the disinfection of the mouth and throat.
  • the former are preferably prepared from alcoholic solutions containing 1 to 5 percent of active substance to which glycerol or flavorings may be added. Lozenges,
  • solid dosage units preferably have a relatively high content of sugar or similar substances and a relatively low content of active substance, for instance 0.2 percent to 20 by weight, as well as the usual conventional additives such a binding agents and flavorings.
  • Solid dosage units in particular tablets, drages (sugar coated tablets) and capsules, are convenient for use in intestinal disinfection and for the oral treatment of urinary tract infections. These units preferably contain from 10 to percent of the compound formula I, to enable the administration of daily doses of from 0.1 to 2.5 grams to adults, or of suitable reduced doses to children. Tablets and drage cores are produced by combining the compounds of formula I with solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatins, preferably with the addition of lubricants such a magnesium or calcium stearate or polyethylene glycols of suitable molecular weight.
  • solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatins, preferably with the addition of lubricants such a magnesium or calcium stearate
  • Drage cores may then be coated, for example with concentrated sugar solutions which can also contain gum arabic, talcum and/or titanium dioxide, or they may be coated with a lacquer dissolved in volatile organic solvents or mixture of solvents.
  • Dyestuffs can be added to these coatings, for instance to diflerentiate between varying dosages.
  • Soft gelatine capsules and other closed capsules consist, for example, of a mixture of gelatines and glycerol, and may contain, for example, mixtures of the compound of formula I with polyethylene glycol.
  • Hard gelatine capsules contain, for example, granulates of an active substance with solid pulverulent carriers, for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatines, and magnesium stearate or stearic acid.
  • solid pulverulent carriers for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatines, and magnesium stearate or stearic acid.
  • a compound of formula I can be present as sole active ingredient, or it may also be combined with other known pharmacologically active, especially antibacterially and/or antimycotically or otherwise antimicrobially active substances, for example to broaden the range of application.
  • the invention also provides a method of protecting an organic material susceptible to bacterial or other microbial attack which comprises treating the material with a nitrofuryl-pyrazole of formula I.
  • the organic material may be, for instance a natural or synthetic polymeric material, a proteinaceous or carbohydrate EXAMPLE 1 a.
  • the product is 5-amino4-cyano-l-ethoxycarbonyl- 3-(5-nitro-2-furyl)-pyrazole having melting point 207 C.
  • the product is S-nitro-furaldehyde a-chloro-N'- ethoxycarbonylhydrazone having melting point 125 C.
  • the mixture is diluted with 500 millilitres of iced water and the precipitate is collected, washed with water and dried. The dried solid is recrystallized from ethyl acetate.
  • the product is 5-amino-4-cyano-l-methyl-3-(5- nitro-2-furyl)-pyrazole having melting point 250 C with decomposition.
  • EXAMPLE 4 The procedure described in Example 3 is carried out using 5-nitro-2-furaldehyde N'-isopropylhydrazone as starting material-instead of 5-nitro-2-furaldehyde N'- methylhydrazone, the reaction conditions being the same.
  • the product is 5-amino-4-cyano-1-is0propyl-3-(5- nitro-2-furyl)-pyrazole.
  • EXAMPLE 5 The procedure described in Example 3 is carried out using 5-nitro-2-furaldehyde N'-n-pentylhydrazone as starting material instead of 5-nitro-2-furaldehyde N'- methylhydrazone, the reaction conditions being the same.
  • the product is 5-amino-4-cyano-l-(n-pentyl)-3-(5- nitro-2-furyl)- pyrazole.
  • Example 6 The procedure described in Example 3 is carried out using 5-nitro-2-furaldehyde N'-(2-hydroxyethyl)- hydrazone as starting material instead of 5-nitro-2-furaldehyde N-methylhydrazone, the reaction conditions being the same.
  • the product is 5-amin0-4-cyanol -(2-hydroxyethyl 3-( 5-nitro-2-furyl)-pyrazole, having melting point 216 C.
  • EXAMPLE 7 The procedure described in Example 3 is carried out using 5-nitro-2-furaldehyde N'-ethylhydrazone as starting material instead of S-nitro-Z-furaldehyde N'- methylhydrazone, the reaction conditions being the same.
  • the product is 5-amino-4-cyanol -ethyl-3-( 5-nitro-2 -furyl)-pyrazole, having melting point 1 89 C.
  • EXAMPLE 8 The procedure described in Example 3 is carried out using 5-nitro-2-furaldehyde N'-n-propylhydrazone as starting material instead of S-nitro-Z-furaldehyde N'- methylhydrazone, the reaction conditions being the same.
  • the product is 5-amino-4-cyano-3-(5-nitro-2-furyl)- l-n-propyl-pyrazole, having melting point 1 65 C.
  • the product is 5-amino-4-cyano-3-(5-nitro-2-furyl)- 1 -n-pentoxycarbonyl-pyrazole.
  • EXAMPLE 10 The procedure described in Example 2 is repeated using 5-nitro-2-furaldehyde N'-(2-hydroxyethyl) hydrazone as starting material in place of 5-nitro-2-furaldehyde N'-methyl hydrazone, the reaction conditions being the same.
  • EXAMPLE 1 Preparation of Tablets 100 g of amino-4-cyano-1-(2-hydroxyethyl)-3-(5- nitro-2-furyl)-pyrazole are mixed with 60.0 g of maize starch and 35.0 g of lactose, the mixture is moistened with a solution of 5.0 g of gelatin and 3.0 g of glycerol in 70.0 g of water and granulated through a sieve. The granulate is mixed with a mixture of 15.0 g of talcum, 10.0 g of maize starch and 2.0 g of magnesium stearate. The resulting mixture is pressed into 1.000 tablets, each containing 100 mg of active substance. If desired, the tablets can be grooved for better adaption of the dosage.
  • Composition 1 is granulated in the heat with composition 11 through a sieve of 1.2 mm mesh diameter. The dried granulate is mixed with composition Ill and the resulting mixture is pressed into 1.000 drage cores. These are then coated with composition IV and dried. The drages obtained weigh 255.0 mg and contain 100 mg of active substance.
  • Citric acid 1.0 g Sodium cyclamate 5.0 g Distilled water 610.0 g Glycerol 100.0 g Sodium carboxymethyl cellulose 4.0 g Sugar 320.0 g
  • R is unsubstituted or hydroxy-substituted alkyl having from one to five carbon atoms, or carbalkoxy having from one to five carbon atoms in the alkyl moiety.
  • a compound according to claim 1, wherein R is methyl. 4. A compound according to claim 1, wherein R is ethyl. 5. A compound according to claim 1, wherein R is n-propyl. 6. A compound according to claim 1, wherein R is 2-hydroxyethyl. 7. A compound according to claim 1, wherein R is ethoxycarbonyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compressor (AREA)
US15209A 1969-03-01 1970-02-27 Substituted 5-nitrofuryl-pyrazoles Expired - Lifetime US3682953A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1106469 1969-03-01

Publications (1)

Publication Number Publication Date
US3682953A true US3682953A (en) 1972-08-08

Family

ID=9979338

Family Applications (1)

Application Number Title Priority Date Filing Date
US15209A Expired - Lifetime US3682953A (en) 1969-03-01 1970-02-27 Substituted 5-nitrofuryl-pyrazoles

Country Status (18)

Country Link
US (1) US3682953A (es)
AT (1) AT290516B (es)
BE (1) BE746655A (es)
BG (1) BG17313A3 (es)
BR (1) BR7017106D0 (es)
CA (1) CA925515A (es)
CH (1) CH526581A (es)
CS (2) CS167277B2 (es)
DE (1) DE2009394A1 (es)
DK (1) DK124032B (es)
ES (1) ES376964A1 (es)
FR (1) FR2034589B1 (es)
GB (1) GB1290913A (es)
IE (1) IE34038B1 (es)
IL (1) IL33980A (es)
NL (1) NL7002459A (es)
NO (1) NO125819B (es)
SE (1) SE366317B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980794A (en) * 1974-05-13 1976-09-14 Eli Lilly And Company Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles
US5698580A (en) * 1994-06-21 1997-12-16 Rational Drug Design Laboratories Antiviral agent containing benzodithiin derivative as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB880256A (en) * 1958-12-05 1961-10-18 Ciba Ltd New pyrazoles and a process for their manufacture
GB905459A (en) * 1958-06-24 1962-09-12 Norwich Pharma Co Anti-coccidial compositions comprising nitrofuran derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB905459A (en) * 1958-06-24 1962-09-12 Norwich Pharma Co Anti-coccidial compositions comprising nitrofuran derivatives
GB880256A (en) * 1958-12-05 1961-10-18 Ciba Ltd New pyrazoles and a process for their manufacture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Burch J. Med. Chem. Vol. 11, pages 79 83 (1968), RS1.J5. *
Sasaki et al. J. Heterocycl. Chem. Vol. 5, pages 243 8 (1968), QD400.J6. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980794A (en) * 1974-05-13 1976-09-14 Eli Lilly And Company Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles
US5698580A (en) * 1994-06-21 1997-12-16 Rational Drug Design Laboratories Antiviral agent containing benzodithiin derivative as active ingredient

Also Published As

Publication number Publication date
BR7017106D0 (pt) 1973-01-04
DK124032B (da) 1972-09-04
IE34038B1 (en) 1975-01-08
BE746655A (fr) 1970-08-27
NO125819B (es) 1972-11-06
ES376964A1 (es) 1972-09-16
NL7002459A (es) 1970-09-03
IL33980A (en) 1973-03-30
CS167276B2 (es) 1976-04-29
IL33980A0 (en) 1970-04-20
CH526581A (de) 1972-08-15
IE34038L (en) 1970-09-01
FR2034589B1 (es) 1973-01-12
BG17313A3 (bg) 1973-07-25
CS167277B2 (es) 1976-04-29
FR2034589A1 (es) 1970-12-11
DE2009394A1 (de) 1971-09-16
GB1290913A (es) 1972-09-27
CA925515A (en) 1973-05-01
SE366317B (es) 1974-04-22
AT290516B (de) 1971-06-11

Similar Documents

Publication Publication Date Title
JPS62161728A (ja) 抗菌剤
EP0195947B1 (de) Beta-Lactamantibiotika, Verfahren zur Herstellung und ihre Verwendung als und in Arzneimitteln
KR20010052236A (ko) 치환된 2-옥소-알칸산-[2-(인돌-3-일)-에틸]아미드
US3830924A (en) Substituted nitroimidazolyl-thiadiazoles as growth promoting agents
US3769295A (en) Nitrofuryl derivatives of 5-substituted isoxazolines
US3716555A (en) New 5-nitrofuryl derivatives
IE49768B1 (en) 6beta-halopenicillanic acid derivatives
US3948913A (en) New 5-nitrofuryl derivatives
US4044130A (en) Compositions for the control of microorganisms
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
US3835165A (en) Nitrofuryl-alpha-halo-hydrazones
DD246993A5 (de) Verfahren zur herstellung von beta-lactamverbindungen
US3682956A (en) Substituted 3-(5-nitro-2-furyl)-pyrazoles
US3632577A (en) 5-nitrofuryl derivatives
US3562286A (en) Nitrofuryl isoxazole derivatives
US3598812A (en) 5-nitrofuryl derivatives
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
US3415838A (en) Nitrogen-containing derivatives of 2,5-dichloro-3-nitrobenzoic acid
US3821382A (en) 5-nitrofuryl derivatives as antibacterial agents
US3562267A (en) Derivatives of 3-(5-nitrofur-2-yl)-5-aminoisoxazoles
US4548934A (en) 4H-1,4-Benzothiazine derivatives
US3923989A (en) Nitro substituted picolinonitriles as anti-bacterial and anti-fungal agents
US3948912A (en) Nitroimidazolyl-triazolo-pyridazine compounds and therapeutic compositions
US3660384A (en) 5-(2-(5-nitro-2-furyl)vinyl)picolinohydroxamic acid
US3910906A (en) Chelocardin derivatives